QUOTE AND NEWS
SeekingAlpha  Jul 21  Comment 
By Kevin Quon: Amyris, Inc. (AMRS) is an integrated renewable products company utilizing an industrial synthetic biology platform capable of taking genetically-engineered yeast to create select products derived from petroleum. The company utilizes...
Motley Fool  Jul 7  Comment 
Intrexon announced the creation of Amyris' flagship molecule in a novel process. What gives?
Motley Fool  Jun 18  Comment 
Amyris is developing way too many molecules to keep track of, so investors should focus on its strategy instead.
Biomass Magazine  Jun 17  Comment 
With the newly revised ASTM standard for jet fuel, Amyris Inc. and Total have are preparing to market a drop-in jet fuel that contains up to 10 percent blends of renewable farnesane. The fuel blend meets performance requirements for Jet A/A-1 fuel.
StreetInsider.com  Jun 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AMYRIS+%28AMRS%29%2C+Total+%28TOT%29+Launch+New+Renewable+Jet+Fuel/9584199.html for the full story.
Motley Fool  Jun 12  Comment 
New financing requires dilution. Big rewards require big risks. Sorting out when new financing is worth it, and when the risks that come with biofuel companies are worth taking will make all of the difference between making money and losing money.
StreetInsider.com  May 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AMYRIS+%28AMRS%29+Prices+%2475M+Aggregate+Convertible+Notes+Offfering/9519372.html for the full story.
Benzinga  May 22  Comment 
Amyris, Inc. (Nasdaq: AMRS), a leading renewable chemicals and fuels company, today announced that it proposes to offer $75 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes"), subject to market conditions and...
Biomass Magazine  May 8  Comment 
Amyris Inc. has released financial results for the first quarter of 2014, reporting strong operational performance with combined inflows from product sales and collaboration inflows of $17.9 million.
SeekingAlpha  May 8  Comment 
The following audio is from a conference call that will begin on May 08, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »




 
TOP CONTRIBUTORS

Amyris Biotechnologies (NASDAQ:AMRS) creates, sells, and distributes renewable products that replace chemicals and fuels made from petroleum. Amyris genetically modifies yeast cells to ferment feedstocks into a series of different target molecules. The company then sells these target molecules to replace additives or fuels which are made from petroleum. The company originally focused on using sugar cane stalks and turned them into farnesene which is key additive in detergents, cosmetics, and transportable fuels among other things. Amyris has continued to diversify both the inputs it can take and the output molecules it can produce. Amyris has pushed to make its products competitive, both in price and effectiveness of replacement, even if they are renewable.[1]

Amyris currently does not have any commercial level efforts in place. It has only established a test facility next to its laboratories in California. The company hopes to expand to commercial distribution levels during 2011 by establishing contracts with sugar cane mills in Brazil. The company has agreed through a letter of intent with a large Brazilian manufacturer to establish a joint venture facility which would turn 10% of their sugar cane into farnesene.[2] The company has also entered into commercialization agreements with large chemical and cosmetic companies such as Procter & Gamble Company (PG).[3]

The company's initial public offering of stock filed on the NASDAQ and went public on the 27 of September 2010. It priced at $16, which was well below the initial price range of $18-$20. The company raised $85M by offering 5.3M shares. The lead underwriter of the deal were J P Morgan Chase (JPM), Morgan Stanley (MS), and Goldman Sachs Group (GS).[4]

Despite not producing at commercial levels, the company has achieved a net revenue for 2009 of $65M. However, due to the high Research & Development costs associated to its developmental stage, it incurred a net loss of $64M.[5]

References

  1. AMRS S-1/A 2010 "Our Company" pg 1
  2. AMRS S-1/A 2010 "Commercial Production" pg 2
  3. AMRS S-1/A 2010 "Commercialization and Distribution" pg 2
  4. Renaissance Capital - IPO "Amyris Biotechnologies prices IPO at $16, below the proposed range" 28 Sept 2010
  5. AMRS S-1/A 2010 "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki